Smart contact lens could revolutionize glaucoma monitoring
NCT ID NCT06689696
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new smart contact lens called miLens that records eye pressure patterns over 24 hours in 86 adults with glaucoma and healthy volunteers. Participants wore the lens in one eye and took smartphone readings every 15 minutes while awake. Researchers compared the lens data to standard office-based eye pressure measurements to see if the device is safe and reliable.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- miLens system (a soft contact lens with imaging and analysis software)
- What this could lead to
- If successful, this could lead to a convenient way to monitor eye pressure at home, helping doctors better manage glaucoma.
- What could go wrong
- This is a completed early-stage study with only 86 participants. The device may not be accurate enough or comfortable for long-term use, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
86 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Jan 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects, aged between 22 and 80 years with: 1. primary open angle glaucoma (POAG) including normal tension glaucoma 2. status as POAG suspect including ocular hypertension (OHTN) 3. no prior diagnosis of POAG/POAG suspect (the subjects in (a) and (b) will henceforth be referred to as "POAG/OHTN" and subjects in (c) will be referred to as "healthy subjects")
- Ages
-
22 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subjects ≥22 to ≤80 years of age 2. Subjects with: * prior diagnosis of POAG in at least one eye, including normal tension glaucoma or prior diagnosis of POAG suspect including OHTN in at least one eye for whom no evidence or suspicion of structural or functional glaucomatous damage exists * Diagnosis of POAG from medical records characterized by open angles and (1) optic nerve cupping consistent with glaucoma, with diffuse or focal thinning of neuroretinal rim or nerve fiber layer defects or a difference in cup/disc ratio \> 0.2, not explained by anisometropia or other non-glaucomatous causes (2) visual field defects consistent with optic nerve cupping, with glaucomatous hemifield test outside normal limits or a pattern standard deviation (PSD) worse than 5th percentile (P\<0.05) by Standard Automated Perimetry, or VF defects with Goldmann visual field test consistent with glaucomatous nerve fiber layer loss including paracentral scotoma, nasal step or arcuate defects * Diagnosis of POAG suspect from medical records established by open angles and IOP ≥22 mmHg (OHTN) OR abnormal appearing optic disc appearance OR glaucomatous visual field defects * no prior history of POAG/OHTN in either eye 3. In subjects with no history of POAG/OHTN, GAT IOP difference between eyes must be ≤ 2 mmHg, with IOP no less than 10 mmHg in both eyes and no greater than 21 mmHg in both eyes. 4. Mean keratometry value is between 7.5 mm and 8.2 mm in at least one eye (the miLens eye) 5. GEN4 miLens contact lens fitting on the subject's eye is acceptable by a slit lamp exam at Day 0 (measurement study visit) 6. Subjects with ability to discontinue habitual IOP-lowering medications, if any, in both eyes on Day 0 visit until the end of the 24-hour wear period (and if applicable, similarly for the Week 1 visit) (No preservative-free topical glaucoma medications will be allowed for the duration of the study) 7. Able to understand, sign and complete the informed consent and available to complete the minimum set of self-acquired smartphone images over the 24-hour contact lens wear period, preferably at an assigned site and likely available for a repeat session after a week Exclusion Criteria: 1. BCVA worse than 20/200 in either eye 2. Greater than 6 diopters spherical equivalent in either eye 3. Greater than 3 diopters of keratometric cylinder in either eye 4. Central corneal thickness greater than 0.60 mm or less than 0.50 mm in either eye (per GAT study guidelines in ANSI Z80.10) 5. Known history of difficulty in obtaining Goldmann IOP measurements or any factors that might contribute to inaccurate Goldmann IOP measurements (e.g. lid squeezing or tremor) 6. Subjects who have had ocular surgery within the last 6 months in either eye 7. Subjects who have had corneal refractive surgery 8. History of Keratoconus, corneal scarring, or other chronic corneal disease in either eye 9. Subjects with contraindication for wearing contact lenses or history of intolerance or difficulties associated with contact lens use including history of dry eye disease 10. Subjects with current signs/symptoms of clinically significant dry eye disease 11. Active eye disease, injury or ocular abnormalities affecting the cornea, conjunctiva, or eyelids or slit lamp findings ≥ grade 3 12. Active inflammation of either eye 13. Active infection of either eye 14. Corneal vascularization of either eye 15. Known allergy to silicone 16. Known allergy to corneal anesthetic 17. Secondary forms of open angle glaucoma (OAG) in either eye 18. Poor or eccentric fixation in either eye 19. Nystagmus 20. Microphthalmos of either eye 21. Buphthalmos of either eye 22. Subject is pregnant, lactating or planning to become pregnant during the course of the study 23. Concurrent participation in any clinical trial 24. Disabling arthritis or limited motor coordination that might limit self-handling of a smart phone with miLens eyepiece attached. 25. Experience using or interacting with miLens and smartphone imaging app during a previous usability or clinical trial 26. Any affiliation with Smartlens and its employees 27. Subjects with any significant dermatologic condition (e.g., history of skin irritation, allergies, skin eczema) that poses a concern for skin contact with the camera eyepiece, based on the Investigator's judgment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Glaucoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
North Bay Eye Associates, Inc.
Petaluma, California, 94954, United States
-
Nvision Clinical Reseacrh, LLC
Fullerton, California, 92835, United States
-
Nvision Clinical Research, LLC
Torrance, California, 90505, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercise shield the eyes of glaucoma patients?
- The 20-Minute squeeze: how eye injections push pressure up
- Can better Follow-Up schedules save sight in glaucoma?
- AI takes on the eye doctor: can software match expert glaucoma grading?
- Portable devices could take the guesswork out of eye pressure checks
- Eye drops may shield the cornea after cataract surgery